Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 137Parkinson Disease 4, Autosomal Dominant Lewy Body 125Melanoma 95Neoplasms 75Squamous Cell Carcinoma of Head and Neck 65Colorectal Neoplasms 42Triple Negative Breast Neoplasms 38Carcinoma, Renal Cell 37Lung Neoplasms 36Stomach Neoplasms 35Head and Neck Neoplasms 34Breast Neoplasms 34Urinary Bladder Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 32Pancreatic Neoplasms 30Ovarian Neoplasms 29Carcinoma, Transitional Cell 25Endometrial Neoplasms 19Recurrence 16Sarcoma 15Esophageal Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Small Cell Lung Carcinoma 13Lymphoma 13Fallopian Tube Neoplasms 13Carcinoma, Squamous Cell 13Lymphoma, Non-Hodgkin 12

Interventions

Doxorubicin 11Ifosfamide 9Radiotherapy 6tazemetostat 4pegfilgrastim 3cixutumumab 3Imatinib Mesylate 3Filgrastim 3Cyclophosphamide 3pazopanib 2Trabectedin 2Sunitinib 2Sorafenib 2Etoposide 2Dacarbazine 2Chemotherapy, Adjuvant 2trofosfamide 1tremelimumab 1temsirolimus 1soblidotin 1sargramostim 1romidepsin 1ribociclib 1reolysin 1poly ICLC 1perifosine 1pembrolizumab 1lorvotuzumab mertansine 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma, Synovial × pembrolizumab × Clear all
NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 15 charts
LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡